Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , .
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes.
In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.
It is important to note that this drug is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis .
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
- Conditions
- ESRDCKD (Chronic Kidney Disease) Stage 5D
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 30
- Registration Number
- NCT06913647
- Locations
- 🇨🇦
Research Institute-McGill University Health Center, Montreal, Quebec, Canada
SGLT2 Inhibitor Utilization Re-perfusion Therapy
- Conditions
- Acute Ischemic Stroke From Large Vessel Occlusion
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06858436
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Target Recruit Count
- 504
- Registration Number
- NCT06851962
- Locations
- 🇪🇸
Hospital Universitario Regional de Málaga, Málaga, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital General Universitario de Valencia (HGUV), Valencia, Spain
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
- Conditions
- Acute Kidney Injury
- Interventions
- Other: Other anti-diabetic drug or no anti-diabetic drug
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 264
- Registration Number
- NCT06528405
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
The Efficacy and Tolerability of Canagliflozin in Healthy Individual
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AgelessRx
- Target Recruit Count
- 30
- Registration Number
- NCT06301529
- Locations
- 🇺🇸
AgelessRx, Ann Arbor, Michigan, United States
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary SyndromeNon-Alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Ping Li,MD
- Target Recruit Count
- 50
- Registration Number
- NCT06256289
Canagliflozin in Advanced Renal Disease With MRI Endpoints
- Conditions
- ESRD, CKD Stage 4, CKD Stage 5
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 92
- Registration Number
- NCT06182839
- Locations
- 🇨🇦
McGill University Health Center, Montreal, Quebec, Canada
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: DPP4 inhibitorDrug: 2nd generation Sulfonylurea
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239990
- Registration Number
- NCT06099067
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Zhang Xiaofeng,MD
- Target Recruit Count
- 20
- Registration Number
- NCT05903703
- Locations
- 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China
Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Mulberry Twig Alkaloid Tablet
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Target Recruit Count
- 60
- Registration Number
- NCT05856578
- Locations
- 🇨🇳
Jianhua Ma, Nanjing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.